Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/handle/10553/139857
Title: | Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series? | Other Titles: | ¿Debe continuar el hidroxiisohexil 3-ciclohexeno carboxaldehído (Lyral®) en las baterías estándar de las pruebas epicutáneas? | Authors: | Hernández Fernández, C. P. Borrego Hernando, Leopoldo Giménez Arnau, A. M. Sanz Sánchez, T. Carrascosa Carrillo, J. M. Zaragoza Ninet, V. Serra Baldrich, E. Miquel Miquel, F. J. Silvestre Salvador, J. F. Córdoba Guijarro, S. Sánchez Gilo, A. Mercader García, P. Navarro Triviño, F. Tous Romero, F. Rodríguez Serna, M. Melé Ninot, G. Ruiz González, I. Gómez de la Fuente, E. Pastor Nieto, M. A. Sánchez-Pedreño Guillén, P. Sánchez Pérez, J. Pereyra Rodríguez, J. J. Gatica Ortega, M. E. González Pérez, R. García Doval, I. Gallego Descalzo, M. A. |
UNESCO Clasification: | 32 Ciencias médicas 320106 Dermatología |
Keywords: | Baseline Series Contact Dermatitis Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde Lyral Patch Tests, et al |
Issue Date: | 2025 | Journal: | Actas dermo-sifiliográficas (Ed. impresa) | Abstract: | Background and objectives: Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyral®, is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021. We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish baseline series. Material and method: We analysed all consecutive patients simultaneously patch-tested with HICC and FM II within the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 through December 31st, 2023. Results: A total of 96 (0.8%) out of 12,029 patients analysed yielded positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II was patched. Conclusions: Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish baseline series and support its exclusion from the European baseline series. | URI: | https://accedacris.ulpgc.es/handle/10553/139857 | ISSN: | 0001-7310 | DOI: | 10.1016/j.ad.2024.10.063 | Source: | Actas Dermo-Sifiliograficas[ISSN 0001-7310], (Enero 2025) |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.